Furthermore, tumor heterogeneity and compensatory signaling pathway activation may attenuate the efficacy of YBX1-targeted therapies, indicating that single-target approaches may be insufficient to fully block its oncogenic functions (27). Here, YBX1 is linked to neoplasm.